R. Charles Coombes

article 1994

Gestrinone in mastalgia: A randomized double blind placebo controlled trial

·doi:10.1016/0960-9776(94)90005-1

78 patients with mastalgia associated with benign breast disease were randomized to treatment with the synthetic steroid gestrinone (2.5 mg twice weekly) or placebo for 3 months. Breast pain scores, which were similar in the two groups prio…

article 1990

Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer

·doi:10.1016/0277-5379(90)90162-m

Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND). 72% of the patients had received no…

article 1986

Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response.

We have compared the response of the N-methyl-N-nitrosourea-induced rat mammary tumor to various endocrine agents with response in patients with breast cancer. To do this, we have induced tumors in 228 animals (65% of intact rats developed …

1985

Detection of Ca antigen in sera from normal individuals and patients with benign and malignant breast disease.

British journal of cancer ·doi:10.1038/bjc.1985.175

Two assay procedures, an inhibition radioimmunoassay (Inhibition-RIA) and an immunoradiometric assay (IRMA), were established for the detection of circulating tumour-associated Ca antigen. There was a good correlation between results (r = 0…

article 1984

TREATMENT OF DISSEMINATED BREAST CANCER WITH TAMOXIFEN, AMINOGLUTETHIMIDE, HYDROCORTISONE, AND DANAZOL, USED IN COMBINATION OR SEQUENTIALLY

·doi:10.1016/s0140-6736(84)91872-5

222 patients with disseminated breast cancer have been randomised to receive either a combination of hormone therapies using tamoxifen, aminoglutethimide with hydrocortisone, and danazol (TAD), or tamoxifen alone. The response to the combin…

article 1983

246 Treatment of disseminated breast cancer with multiple hormone therapy using tamoxifen, danazol, aminoglutethimide and hydrocortisone

·doi:10.1016/0022-4731(83)91746-6

article 1983

Danazol treatment for advanced breast cancer

·doi:10.1007/bf00255761

Pre-menopausal (14) and post-menopausal (55) patients with advanced breast cancer were treated with danazol (Danol) for periods ranging between 3 days and 30 months. Of these, 10 patients (14.9%) responded to treatment for 3-19 months (mean…

article 1983

Prognostic significance of serum prolactin levels in advanced breast cancer

·doi:10.1038/bjc.1983.129

Serum prolactin concentrations were measured in 135 postmenopausal patients with advanced breast cancer prior to their treatment with one of 3 endocrine therapies: aminoglutethimide (AG), tamoxifen (T) + AG, or T + AG + danazol. The mean le…

article 1982

Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone.

Multiple-endocrine therapy with combinations of various types of treatment has not been evaluated properly in spite of the success of individual types of hormone treatment. This paper reports the early results of a randomized controlled cli…

article 1982

Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer

·doi:10.1038/bjc.1982.161

Gonadotrophins, oestradiol, androstenedione, testosterone and dehydroepiandrosterone sulphate (DHAS) were measured sequentially in 72 patients with advanced breast cancer receiving endocrine therapy of various types. Tamoxifen significantly…

article 1981

Danazol treatment of advanced breast cancer.

Danazol, an effective agent in the treatment of benign breast disease, has been administrated to 41 patients with advanced breast cancer. These patients were treated with danazol for periods ranging from 1 to 40 weeks and responses were see…